OncoSec Medical Inc (ONCSQ)

[chickpea598]

The FDA accepts for review Merck's (NYSE:MRK) supplemental Biologics License Application (sBLA) seeking approval of the use of KEYTRUDA (pembrolizumab) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, a Breakthrough Therapy designation. The agency's action date (PDUFA) is December 24.

The Keytruda label expansions will continue.

Another note about T-Vec. The combination of T-Vex and Opdivo yielded in the 50-60% overall response rate.

EP IL12 + Keytruda should at least equal these results.